Alamar Biosciences
ALMR
26.48
-2.20
-7.67%
Alamar Biosciences
US · ALMR
#2657 by market cap
Listed 2026
26.48
-2.20
-7.67%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 14 in the most recent period (2026/Q3).
- Total institutional ownership fell 7.4 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 65.10% -7.41pp
- Institutions
- 125 +14
- As of
- 2026/Q3 vs. prior period
Holder types
VC/PE Fund34.14%
Mutual Fund22.37%
Individual/Insider10.42%
Hedge Fund7.80%
Government Pension Fund0.33%
Public Company0.29%
Family Office/Trust0.11%
Other24.48%
Top holders as of 2026-11-03
Qiming Weichuang Venture Capital Management (Shanghai) Company Limited
13.09% · 9.10M sh
IIF Management Company LLC
9.16% · 6.36M sh
Zhuhai Sherpa Equity Investment Management Company Limited
6.90% · 4.80M sh
Sands Capital Management, LLC
6.09% · 4.23M sh
Sands Capital Alternatives, LLC
6.10% · 4.23M sh
Yuling Luo
4.44% · 3.09M sh
Lian Luo
4.29% · 2.98M sh
Samsara BioCapital LLC
3.57% · 2.48M sh
T. Rowe Price Group, Inc.
3.19% · 2.21M sh
Emerald Advisers, LLC
1.88% · 1.30M sh
Braidwell LP
1.56% · 1.08M sh
ARK Investment Management LLC
1.79% · 1.24M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 23 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | 13.09% |
| Yuling Luo | Chairperson & CEO | 4.44% |
| Shiping Chen | Co-Founder, COO & Director | 1.04% |
| Timothy White | President | 0.65% |
| Nicholas Naclerio | Independent Director | -- |
| Franklin Witney | Lead Independent Director | -- |
| Robert Ragusa | Director | -- |
| IIF Management Company LLC | -- | -- |
| Justin McAnear | Chief Financial Officer | -- |
| Rebecca Chambers | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-02 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Open Market Disposition | -111,313 | $29.89 |
| 2026-11-01 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Open Market Disposition | -187,636 | $29.84–33.31 |
| 2026-10-27 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Open Market Disposition | -185,731 | $30.33–33.11 |
| 2026-10-25 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Open Market Disposition | -280,458 | $29.35–31.07 |
| 2026-10-21 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Open Market Disposition | -342,626 | $29.00–30.81 |
| 2026-10-19 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Open Market Disposition | -217,512 | $26.34–28.44 |
| 2026-10-15 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Open Market Disposition | -173,673 | $27.02–28.26 |
| 2026-10-13 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Intent to Sell (Form 144) | -1,558,858 | $23.52 |
| 2026-10-13 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Intent to Sell (Form 144) | -435,468 | $23.52 |
| 2026-10-13 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Intent to Sell (Form 144) | -363,729 | $23.52 |
| 2026-10-13 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Intent to Sell (Form 144) | -41,945 | $23.53 |
| 2026-09-13 | John Brottem | General Counsel | Other Acquisition | +29,000 | -- |
| 2026-09-13 | John Brottem | General Counsel | Other Derivative Acquisition | +85,000 | $27.99 |
| 2026-08-31 | Robert Ragusa | Director | Other Acquisition | +5,686 | -- |
| 2026-08-31 | Robert Ragusa | Director | Other Derivative Acquisition | +25,599 | $29.36 |
| 2026-04-19 | Nicholas Naclerio | Independent Director | Other Acquisition | +5,686 | -- |
| 2026-04-19 | Franklin Witney | Lead Independent Director | Other Derivative Acquisition | +206,781 | $0.59–7.60 |
| 2026-04-19 | Franklin Witney | Lead Independent Director | Other Derivative Disposition | -206,781 | $0.59–7.60 |
| 2026-04-19 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Other Acquisition | +10,594,547 | -- |
| 2026-04-19 | Qiming Weichuang Venture Capital Management (Shanghai) Company Limited | -- | Derivative Exercise and Sale | -10,594,547 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Alamar Biosciences discussion 0 comments